Vor Biopharma Inc. (NASDAQ:VOR) Given Consensus Rating of “Moderate Buy” by Analysts

Vor Biopharma Inc. (NASDAQ:VOR) has received a consensus rating of “Moderate Buy” from the eleven analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $42.25.

A number of analysts have commented on the company. Wedbush lifted their price target on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Weiss Ratings upgraded Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 30th. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th. Finally, Jefferies Financial Group upgraded shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th.

Insider Buying and Selling

In other news, Director Ra Capital Management, L.P. sold 165,150 shares of the company’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total value of $2,604,415.50. Following the sale, the director directly owned 2,402,095 shares of the company’s stock, valued at $37,881,038.15. This represents a 6.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. acquired a new position in Vor Biopharma during the fourth quarter valued at $36,000. Goldman Sachs Group Inc. grew its position in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the period. XTX Topco Ltd purchased a new position in shares of Vor Biopharma during the 2nd quarter valued at about $66,000. Chung Wu Investment Group LLC purchased a new position in shares of Vor Biopharma during the 4th quarter valued at about $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in shares of Vor Biopharma in the 4th quarter valued at about $134,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Price Performance

NASDAQ VOR opened at $18.09 on Wednesday. Vor Biopharma has a 12-month low of $6.50 and a 12-month high of $53.00. The company has a fifty day simple moving average of $15.94 and a two-hundred day simple moving average of $15.02.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. On average, research analysts expect that Vor Biopharma will post -2.51 earnings per share for the current year.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).